Evaluation of the Preclinical Efficacy of Lurbinectedin in Malignant Pleural Mesothelioma

SIMPLE SUMMARY: The marine drug lurbinectedin revealed an unprecedented efficacy against patient-derived malignant pleural mesothelioma cells, regardless of the histological type and the BAP1 mutation status. By inducing strong DNA damages, it dramatically arrested cell cycle progression and induced...

Descripción completa

Detalles Bibliográficos
Autores principales: Anobile, Dario P., Bironzo, Paolo, Picca, Francesca, Lingua, Marcello F., Morena, Deborah, Righi, Luisella, Napoli, Francesca, Papotti, Mauro G., Pittaro, Alessandra, Di Nicolantonio, Federica, Gigliotti, Chiara, Bussolino, Federico, Comunanza, Valentina, Guerrera, Francesco, Sandri, Alberto, Leo, Francesco, Libener, Roberta, Aviles, Pablo, Novello, Silvia, Taulli, Riccardo, Scagliotti, Giorgio V., Riganti, Chiara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8151304/
https://www.ncbi.nlm.nih.gov/pubmed/34066159
http://dx.doi.org/10.3390/cancers13102332

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8151304/
https://www.ncbi.nlm.nih.gov/pubmed/34066159
http://dx.doi.org/10.3390/cancers13102332

Ejemplares similares